Quick Answer
HOOKIPA Pharma Inc. reported Research And Development Expense of $68.51 million for the year ending 2024.
- HOOKIPA Pharma Inc. showed a decrease of -20.7% in Research And Development Expense from 2023 to 2024.
- This data is from HOOKIPA Pharma Inc.'s annual report (Form 10-K), filed with the SEC on February 28, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $4.97 million | Q2 2018: $6.21 million | Q3 2018: $6.17 million | Q1 2019: $10.18 million | Q2 2019: $13.93 million | Q3 2019: $11.03 million | Q1 2020: $11.53 million | Q2 2020: $11.56 million | Q3 2020: $16.01 million | Q1 2021: $20.16 million | Q2 2021: $19.57 million | Q3 2021: $20.70 million | Q1 2022: $16.62 million | Q2 2022: $16.15 million | Q3 2022: $18.29 million | Q1 2023: $20.93 million | Q2 2023: $19.71 million | Q3 2023: $24.63 million | Q1 2024: $20.17 million | Q2 2024: $19.75 million | Q3 2024: $15.57 million | Q1 2025: $12.86 million.
- Over the full 8 years of available data (2017 to 2024), HOOKIPA Pharma Inc.'s Research And Development Expense has grown by 601.1%.
- Historical annual values: Fiscal year 2024: $68.51 million | Fiscal year 2023: $86.42 million | Fiscal year 2022: $68.65 million | Fiscal year 2021: $82.85 million | Fiscal year 2020: $54.79 million | Fiscal year 2019: $46.31 million | Fiscal year 2018: $21.97 million | Fiscal year 2017: $9.77 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: